跳至主要内容
临床试验/EUCTR2011-005441-13-ES
EUCTR2011-005441-13-ES进行中(未招募)1 期

Evaluation of efficacy and safety of autologous MSCs combined to biomaterials to enhance bone healing in patients with delayed consolidation after long bone fracture requiring graft apposition or alternative orthobiologics. - REBORNE - ORthoCT1

INSERM0 个研究点目标入组 30 人开始时间: 2012年5月29日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
INSERM
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • - age 18 to 65 both sexes
  • - traumatic isolated closed or open Gustilo I and II humerus, tibial or femur diaphyseal or metaphysodiaphyseal fracture status delayed union or non union
  • - at least 3 months from acute fracture
  • - able to provide informed consent, and signed informed consent
  • - patients (by themselves) should have medical health care coverage to be included in a research study
  • - able to understand and accept the study constraints
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control
  • - participation in another therapeutic trial previous 3 months
  • - delayed union or non-union related to iatrogeny
  • - segmental bone loss requiring therapy
  • - vascular or neural injury
  • - impossibility to meet appointments for the follow up
  • - other fractures causing interference with weight bearing
  • - infection
  • viceral injuries of diseases interfering with callus formation
  • - history of bone harvesting on iliac crest contraindicating bone-marriw aspiration
  • - corticoid or immunosuppressive therapy more than one week in the 3 mionths prior ti study inclusion
  • - history of prior concurrent diagnosis of HIV, Hepatitis B or C infection
  • - insulin dependent diabetes
  • - autoimmune inflammatory disease
  • - current treatment by bisphonate or stopped in the 3 months prior to stydy inclusion
  • - subject legally protected, under legal guardianship, deprived of their liberty by judicial or administrative decision, subject of psychiatric care, or admission a health facility.

研究者

发起方
INSERM

相似试验

进行中(未招募)
1 期
Development of tissue engineering therapy to treat patients with delayed consolidation after fracture of long bones.Closed or open Gustilo I ans II humerus, tibial or femur diaphyseal or metaphysodiaphyseal fracture.MedDRA version: 14.1 Level: PT Classification code 10017081 Term: Fracture delayed union System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2011-005441-13-DEINSERM30
进行中(未招募)
不适用
Development of a therapy to treat patients with delayed consolidation after fracture of long bonesClosed or open Gustilo I and II humerus, tibial or femur diaphyseal or metaphysodiaphyseal fractureMedDRA version: 14.1Level: PTClassification code 10017081Term: Fracture delayed unionSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2011-005441-13-ITINSERM - Institut National de la Sant? et de la Recherche m?dicale30
尚未招募
1 期
Safety and clinical effectiveness of autologous mesenchymal stromal cell infusion as adjuncttreatment in patients with Idiopathic Pulmonary FibrosisJ84.1Other interstitial pulmonary diseases with fibrosis
DRKS00008790The Republican Research and Practical Centre for Pulmonology and TB40
已完成
不适用
Evaluation of safety and efficacy of autologous stentless mitral valve replacement: pilot studymitral valve stenosis, mitral valve stenosis and regurgitation
JPRN-UMIN000026020Kyoto Prefectural University of Medicine
招募中
Unknown
Clinical Study of Safety and Efficacy of Autologous Mesenchymal Stem Cells for Periodontal Tissue Regeneration TherapyPeriodontal Disease
JPRN-jRCTb070230008Cho Yasushi22